Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Cantor Fitzgerald
Merck
Fish and Richardson
Express Scripts
UBS
Covington
Boehringer Ingelheim
Citi
Daiichi Sankyo

Generated: January 22, 2018

DrugPatentWatch Database Preview

ADDERALL 30 Drug Profile

« Back to Dashboard

When do Adderall 30 patents expire, and when can generic versions of Adderall 30 launch?

Adderall 30 is a drug marketed by Teva Womens and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in six countries.

The generic ingredient in ADDERALL 30 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.
Summary for ADDERALL 30
International Patents:6
US Patents:1
Applicants:1
NDAs:1
Clinical Trials: 30
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADDERALL 30 at DailyMed
Drug patent expirations by year for ADDERALL 30

US Patents and Regulatory Information for ADDERALL 30

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens ADDERALL 30 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-010 May 12, 1997 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ADDERALL 30
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 5 mg, 10 mg, 20 mg, 30 mg ➤ Subscribe 11/18/2009

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Covington
Moodys
McKesson
Fish and Richardson
Colorcon
Mallinckrodt
Farmers Insurance
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot